Why Boehringer Just Handed Its Skin Drug to a Rival

Because focus is expensive, and Boehringer is making a choice. The company has been quietly rebalancing its portfolio throughout 2025 and 2026, doubling down on immunology partnerships while shedding dermatology assets that need a specialist's touch. In 2025 alone, Boehringer inked collaborations with Cue Biopharma (B-cell depletion in autoimmune disease), CDR-Life (a trispecific T-cell engager), and Kyowa Kirin (a small-molecule autoimmune compound).

The pattern is clear: Boehringer wants to own the broader immunology space. Rare dermatology? That's someone else's game.

And LEO Pharma is the perfect someone else.

LEO's Dermatology Shopping Spree

LEO Pharma has been on an absolute tear, building what looks like the most focused dermatology pipeline in the industry. The Danish company isn't trying to be everything to everyone. It's trying to be the single best company in the world at treating skin diseases, and it's buying its way there at remarkable speed.

Consider the recent moves: LEO expanded its late-stage pipeline with new trials for Anzupgo (delgocitinib cream) in conditions like palmoplantar pustulosis. It partnered with Gilead on an oral STAT6 program. In 2026, it acquired Replay and its gene therapy platform, then picked up dersimelagon from Tanabe Pharma with FDA priority review acceptance.

SPEVIGO fits this strategy like a glove. LEO isn't just buying a drug; it's buying a platform to expand into rare and difficult-to-treat skin diseases. The company is already planning a Phase 3 trial of spesolimab in pyoderma gangrenosum (a painful ulcerative skin condition), recruiting across 103 sites. Long-term extension studies are underway in hidradenitis suppurativa as well.

This isn't a one-indication purchase. It's a franchise play.

The IL-36 Pathway Has Room to Run

What makes this deal especially interesting is the competitive landscape, or rather, the lack of one. In 2026, the IL-36 receptor antagonist space is essentially spesolimab and... spesolimab. The main would-be competitor, imsidolimab, hasn't shown a comparable late-stage trial footprint. There's no visible Phase 3 head-to-head threat on the horizon.

That gives LEO something rare in pharma: time. Time to build the brand, expand the label, and generate the kind of long-term safety and efficacy data (like the ongoing five-year EFFISAYIL ON extension study) that makes a drug nearly impossible to displace.

It also positions LEO at the frontier of a broader industry trend. Pharma has spent the last decade focused on IL-17 and IL-23 pathways for inflammatory skin diseases. Those targets work well, but they don't work for everything. The IL-36 pathway represents a genuinely different biological mechanism, one that's particularly relevant for neutrophilic skin inflammation rather than the T-cell-driven inflammation those older targets address.

The Bigger Picture: Inflammation's Next Chapter

Zoom out, and the Boehringer/LEO deal is one data point in a much larger story. The inflammation space is fragmenting into increasingly specific targets, and pharma companies are placing bets accordingly.

TL1A is emerging as a high-conviction target in inflammatory bowel disease, with multiple Phase 3 programs running. TYK2 inhibitors are going after the upstream signaling that drives multiple inflammatory pathways at once. TSLP and IL-33 are reshaping how we think about allergic inflammation. Even FcRn (a receptor that recycles antibodies) is becoming a major therapeutic target for autoimmune diseases.

The common thread? Companies are moving beyond the "blockbuster cytokine" playbook and getting surgical about which specific immune pathways to block in which specific diseases. The IL-36/GPP connection is a textbook example of that precision approach.

Who Wins?

For Boehringer, this deal is about discipline. Selling an approved drug is never easy, but €90 million upfront (plus royalties) lets the company fund its broader immunology ambitions without stretching across too many therapeutic areas.

For LEO Pharma, it's about conviction. The company is betting that being the undisputed leader in medical dermatology is more valuable than being a mid-tier player across multiple specialties. Every deal it signs reinforces that thesis.

And for patients with GPP? They get a company that's fully committed to their disease, with the resources and focus to expand research into conditions that most pharma companies would consider too small to bother with.

Sometimes the best thing a company can do with a great drug is give it to someone who'll love it more.

The $3.95 Million Drug That Costs More Than Most Houses

Ultragenyx just priced its new gene therapy Fayuvi at $3.95 million per patient, making it the second most expensive drug in the world. It's a one-time treatment for a fatal childhood brain disease with zero alternatives, and it's reigniting the fiercest debate in biotech: who pays for a genetic cure?